Elanco Animal Health Investors Warned of Class Action Lawsuit for Losses
Elanco Animal Health Investors who experienced losses recently received a notification about a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) and some of its senior executives. This suit alleges potential violations of federal securities laws. If you’re an investor in Elanco, you’re invited to gather more details by visiting the Bleichmar Fonti & Auld LLP website before the December 6 deadline.
The lawsuit claims that Elanco focuses on developing products to treat animal diseases, with two key treatments currently under FDA review. These treatments, Zenrelia for dog dermatitis and Credelio Quattro for parasites, were anticipated to receive FDA approval by June 2024. However, on June 27, 2024, Elanco stated the FDA would not approve either drug by the expected date, impacting the stock price significantly.
If you’ve invested in Elanco Animal Health Incorporated (NYSE: ELAN), it’s essential to know your legal options. Whether you’re seeking representation or additional information, you can reach out to Bleichmar Fonti & Auld LLP. The firm operates on a contingency fee basis, meaning there’s no cost upfront for shareholders. Investors aren’t burdened with court expenses or other litigation costs.
Bleichmar Fonti & Auld LLP is recognized for its expertise in securities class actions and shareholder litigation. With numerous successful cases, including significant recoveries from prominent companies, the firm is a reliable resource for investors seeking guidance in legal matters related to securities.
For more information about the lawsuit and legal options available to Elanco Animal Health investors, visit the Bleichmar Fonti & Auld LLP website or contact Ross Shikowitz at ross@bfalaw.com or 212-789-3619. Remember, past results do not guarantee future outcomes, but having the right support can make a difference in protecting your investment interests.
